JP2543298B2 - ビス（フェニル）エタン誘導体 - Google Patents

ビス（フェニル）エタン誘導体

Info

Publication number: JP2543298B2
Authority: JP; Japan
Prior art keywords: formula; compound; och; compounds; tumor
Prior art date: 1991-10-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP4277054A

Other languages

English (en)

Japanese (ja)

Other versions

JPH05213828A (ja

Inventor

ペーター・ヌスバウマー

アントン・シュテュッツ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-16

Filing date

1992-10-15

Publication date

1996-10-16

1992-10-15 Application filed by Sandoz AG filed Critical Sandoz AG

1993-08-24 Publication of JPH05213828A publication Critical patent/JPH05213828A/ja

1996-10-16 Application granted granted Critical

1996-10-16 Publication of JP2543298B2 publication Critical patent/JP2543298B2/ja

2011-10-16 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

BSZXAFXFTLXUFV-UHFFFAOYSA-N 1-phenylethylbenzene Chemical class C=1C=CC=CC=1C(C)C1=CC=CC=C1 BSZXAFXFTLXUFV-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 58
150000003839 salts Chemical group 0.000 claims abstract description 10
206010028980 Neoplasm Diseases 0.000 claims description 22
125000003545 alkoxy group Chemical group 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
230000003463 hyperproliferative effect Effects 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 4
-1 methyl 5- [2- (2,5-dimethoxyphenyl) -ethyl] -2-hydroxybenzoic acid ester Chemical class 0.000 claims description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 2
229940124597 therapeutic agent Drugs 0.000 claims 2
230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
230000001093 anti-cancer Effects 0.000 abstract description 4
230000003389 potentiating effect Effects 0.000 abstract description 2
238000000034 method Methods 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
210000004027 cell Anatomy 0.000 description 17
241001465754 Metazoa Species 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 10
238000002844 melting Methods 0.000 description 10
230000008018 melting Effects 0.000 description 10
238000012360 testing method Methods 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000000203 mixture Substances 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
241000699670 Mus sp. Species 0.000 description 6
238000003556 assay Methods 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
125000002252 acyl group Chemical group 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 5
125000004356 hydroxy functional group Chemical group O* 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
102000001301 EGF receptor Human genes 0.000 description 4
108060006698 EGF receptor Proteins 0.000 description 4
206010061902 Pancreatic neoplasm Diseases 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
239000013078 crystal Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 4
230000012010 growth Effects 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
GZOFTOHENYHNMS-UHFFFAOYSA-N methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC(CCC=2C(=CC=C(OC)C=2)OC)=C1 GZOFTOHENYHNMS-UHFFFAOYSA-N 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
201000002528 pancreatic cancer Diseases 0.000 description 4
239000000126 substance Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000003513 alkali Substances 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000000624 ear auricle Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
LUKRGJFKNNAAJA-UHFFFAOYSA-N methyl 5-[2-(2,5-dimethoxyphenyl)ethynyl]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC(C#CC=2C(=CC=C(OC)C=2)OC)=C1 LUKRGJFKNNAAJA-UHFFFAOYSA-N 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
101800004564 Transforming growth factor alpha Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
210000001339 epidermal cell Anatomy 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
238000005809 transesterification reaction Methods 0.000 description 2
125000004665 trialkylsilyl group Chemical group 0.000 description 2
FVUDWHPJVYTKDT-UHFFFAOYSA-M (2,5-dimethoxyphenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].COC1=CC=C(OC)C(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 FVUDWHPJVYTKDT-UHFFFAOYSA-M 0.000 description 1
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
XYJAHKATEAXAOA-UHFFFAOYSA-N 2-ethynyl-1,4-dimethoxybenzene Chemical group COC1=CC=C(OC)C(C#C)=C1 XYJAHKATEAXAOA-UHFFFAOYSA-N 0.000 description 1
BGJIXAANOBCFEU-UHFFFAOYSA-N 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoic acid Chemical compound COC1=CC=C(OC)C(CCC=2C=C(C(O)=CC=2)C(O)=O)=C1 BGJIXAANOBCFEU-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000011729 BALB/c nude mouse Methods 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
238000007341 Heck reaction Methods 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
101150109894 TGFA gene Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000000448 cultured tumor cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000020176 deacylation Effects 0.000 description 1
238000005947 deacylation reaction Methods 0.000 description 1
230000020335 dealkylation Effects 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
210000000613 ear canal Anatomy 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
AYGAWHWLLYDEDI-UHFFFAOYSA-N ethyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OCC)=CC(CCC=2C(=CC=C(OC)C=2)OC)=C1 AYGAWHWLLYDEDI-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
HJTFUJQRQKCILC-UHFFFAOYSA-N methyl 2-acetyloxy-5-[2-(2,5-dimethoxyphenyl)ethyl]benzoate Chemical compound C1=C(OC(C)=O)C(C(=O)OC)=CC(CCC=2C(=CC=C(OC)C=2)OC)=C1 HJTFUJQRQKCILC-UHFFFAOYSA-N 0.000 description 1
NRSWJTRJHPRZMH-UHFFFAOYSA-N methyl 2-hydroxy-5-iodobenzoate Chemical compound COC(=O)C1=CC(I)=CC=C1O NRSWJTRJHPRZMH-UHFFFAOYSA-N 0.000 description 1
XJKWVPNWHOCFBR-UHFFFAOYSA-N methyl 5-formyl-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(C=O)=CC=C1O XJKWVPNWHOCFBR-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
231100001221 nontumorigenic Toxicity 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000011435 rock Substances 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Polyesters Or Polycarbonates (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
External Artificial Organs (AREA)
Photoreceptors In Electrophotography (AREA)
Paints Or Removers (AREA)

JP4277054A 1991-10-16 1992-10-15 ビス（フェニル）エタン誘導体 Expired - Fee Related JP2543298B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919121943A GB9121943D0 (en)	1991-10-16	1991-10-16	Organic compounds,processes for their production and their use
GB9121943		1991-10-16

Publications (2)

Publication Number	Publication Date
JPH05213828A JPH05213828A (ja)	1993-08-24
JP2543298B2 true JP2543298B2 (ja)	1996-10-16

Family

ID=10703010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4277054A Expired - Fee Related JP2543298B2 (ja)	1991-10-16	1992-10-15	ビス（フェニル）エタン誘導体

Country Status (27)

Country	Link
US (1)	US5488135A (2)
EP (1)	EP0539326B1 (2)
JP (1)	JP2543298B2 (2)
KR (1)	KR930007880A (2)
AT (1)	ATE136536T1 (2)
AU (1)	AU653441B2 (2)
CA (1)	CA2080555C (2)
CZ (1)	CZ282473B6 (2)
DE (1)	DE69209771T2 (2)
DK (1)	DK0539326T3 (2)
ES (1)	ES2087499T3 (2)
FI (1)	FI924657L (2)
GB (1)	GB9121943D0 (2)
GR (1)	GR3019856T3 (2)
HK (1)	HK146696A (2)
HU (2)	HU215151B (2)
IL (1)	IL103417A (2)
MX (1)	MX9205921A (2)
NO (1)	NO178540C (2)
NZ (1)	NZ244730A (2)
PH (1)	PH31113A (2)
RO (1)	RO111074B1 (2)
RU (1)	RU2118311C1 (2)
SG (1)	SG50542A1 (2)
SK (1)	SK312592A3 (2)
TW (1)	TW221051B (2)
ZA (1)	ZA928021B (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7103979B2 (en)	2001-04-20	2006-09-12	Hitachi Koki Co., Ltd.	Portable electric cutting device with blower mechanism
US7219435B2 (en)	2002-10-22	2007-05-22	Hitachi Koki Co., Ltd.	Portable electric cutting device with blower mechanism
US7275326B2 (en)	2004-01-26	2007-10-02	Hitachi Koki Co., Ltd.	Portable electric cutting apparatus

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP9801828A3 (en) *	1995-03-14	2001-02-28	Novartis Ag	Benzoic acid, quinoline and quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
DE10015525A1 (de) *	2000-03-30	2001-10-11	Deutsches Krebsforsch	Synthetische Derivate von Lunularsäure, Arzneimittel enthaltend diese Verbindung, Verfahren zur Herstellung der Lunularsäurederivate sowie deren Verwendung
ES2204300B1 (es) *	2002-07-18	2005-05-01	J. URIACH & CIA S.A.	Nuevos derivados del acido 2,4-dihidroxibenzoico.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE293108C (2) *
DE269619C (2) *
US3657430A (en) *	1969-06-25	1972-04-18	Merck & Co Inc	Composition and methods for treating inflammation
DE3066406D1 (en) *	1979-09-13	1984-03-08	Wellcome Found	Diaryl compounds and pharmaceutical formulations containing them
JPH01501790A (ja) *	1986-11-19	1989-06-22	ケメックス　ファーマシューティカルズ，インコーポレイティド	リポキシゲナーゼ阻害剤
WO1988003806A1 (en) *	1986-11-19	1988-06-02	Chemex Pharmaceuticals, Inc.	Pharmacologically active compositions of catecholic butanes with zinc
HUT60458A (en) *	1991-02-01	1992-09-28	Sandoz Ag	Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
CA2102780C (en) *	1991-05-10	2007-01-09	Alfred P. Spada	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase

1991
- 1991-10-16 GB GB919121943A patent/GB9121943D0/en active Pending
1992
- 1992-10-05 HU HU9203156A patent/HU215151B/hu not_active IP Right Cessation
- 1992-10-13 SG SG1996004564A patent/SG50542A1/en unknown
- 1992-10-13 DK DK92810782.0T patent/DK0539326T3/da active
- 1992-10-13 EP EP92810782A patent/EP0539326B1/en not_active Expired - Lifetime
- 1992-10-13 DE DE69209771T patent/DE69209771T2/de not_active Expired - Lifetime
- 1992-10-13 ES ES92810782T patent/ES2087499T3/es not_active Expired - Lifetime
- 1992-10-13 AT AT92810782T patent/ATE136536T1/de not_active IP Right Cessation
- 1992-10-14 IL IL10341792A patent/IL103417A/xx not_active IP Right Cessation
- 1992-10-14 CA CA002080555A patent/CA2080555C/en not_active Expired - Fee Related
- 1992-10-14 AU AU27044/92A patent/AU653441B2/en not_active Ceased
- 1992-10-14 RO RO92-01311A patent/RO111074B1/ro unknown
- 1992-10-14 SK SK3125-92A patent/SK312592A3/sk unknown
- 1992-10-14 CZ CS923125A patent/CZ282473B6/cs not_active IP Right Cessation
- 1992-10-14 NZ NZ244730A patent/NZ244730A/en unknown
- 1992-10-14 NO NO923983A patent/NO178540C/no unknown
- 1992-10-14 FI FI924657A patent/FI924657L/fi unknown
- 1992-10-15 RU RU92004377A patent/RU2118311C1/ru active
- 1992-10-15 KR KR1019920018971A patent/KR930007880A/ko not_active Ceased
- 1992-10-15 MX MX9205921A patent/MX9205921A/es not_active IP Right Cessation
- 1992-10-15 JP JP4277054A patent/JP2543298B2/ja not_active Expired - Fee Related
- 1992-10-16 US US07/962,370 patent/US5488135A/en not_active Expired - Lifetime
- 1992-10-16 ZA ZA928021A patent/ZA928021B/xx unknown
- 1992-10-16 PH PH45119A patent/PH31113A/en unknown
- 1992-10-17 TW TW081108265A patent/TW221051B/zh active
1995
- 1995-06-19 HU HU95P/P00247P patent/HU211233A9/hu unknown
1996
- 1996-05-07 GR GR960401241T patent/GR3019856T3/el unknown
- 1996-08-01 HK HK146696A patent/HK146696A/en not_active IP Right Cessation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7103979B2 (en)	2001-04-20	2006-09-12	Hitachi Koki Co., Ltd.	Portable electric cutting device with blower mechanism
US7219435B2 (en)	2002-10-22	2007-05-22	Hitachi Koki Co., Ltd.	Portable electric cutting device with blower mechanism
US7516553B2 (en)	2002-10-22	2009-04-14	Hitachi Koki Co., Ltd.	Portable electric cutting device with blower mechanism
US7275326B2 (en)	2004-01-26	2007-10-02	Hitachi Koki Co., Ltd.	Portable electric cutting apparatus
US7861417B2 (en)	2004-01-26	2011-01-04	Hitachi Koki Co., Ltd.	Portable electric cutting apparatus

Also Published As

Publication number	Publication date
NO923983L (no)	1993-04-19
SG50542A1 (en)	2000-05-23
CA2080555A1 (en)	1993-04-17
HK146696A (en)	1996-08-09
GB9121943D0 (en)	1991-11-27
DK0539326T3 (da)	1996-05-20
AU653441B2 (en)	1994-09-29
DE69209771D1 (de)	1996-05-15
FI924657A0 (fi)	1992-10-14
EP0539326B1 (en)	1996-04-10
ES2087499T3 (es)	1996-07-16
CZ282473B6 (cs)	1997-07-16
ATE136536T1 (de)	1996-04-15
TW221051B (2)	1994-02-11
HUT62850A (en)	1993-06-28
RO111074B1 (ro)	1996-06-28
CZ312592A3 (en)	1993-05-12
PH31113A (en)	1998-02-23
JPH05213828A (ja)	1993-08-24
FI924657A7 (fi)	1993-04-17
ZA928021B (en)	1994-04-18
EP0539326A2 (en)	1993-04-28
US5488135A (en)	1996-01-30
NO923983D0 (no)	1992-10-14
RU2118311C1 (ru)	1998-08-27
NO178540C (no)	1996-04-17
CA2080555C (en)	2003-12-30
FI924657L (fi)	1993-04-17
MX9205921A (es)	1993-04-01
SK312592A3 (en)	1995-03-08
KR930007880A (ko)	1993-05-20
HU215151B (hu)	1998-12-28
AU2704492A (en)	1993-04-22
IL103417A (en)	1997-01-10
EP0539326A3 (en)	1993-07-21
IL103417A0 (en)	1993-03-15
NO178540B (no)	1996-01-08
DE69209771T2 (de)	1996-10-31
HU211233A9 (en)	1995-11-28
NZ244730A (en)	1994-10-26
GR3019856T3 (en)	1996-08-31
HU9203156D0 (en)	1992-12-28

Legal Events

Date	Code	Title	Description
2004-06-15	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2005-06-14	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2006-06-20	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2007-06-28	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20070725 Year of fee payment: 11
2007-07-03	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080725 Year of fee payment: 12
2008-07-03	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080725 Year of fee payment: 12
2008-07-08	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20090725 Year of fee payment: 13
2009-07-02	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20090725 Year of fee payment: 13
2009-07-07	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20100725 Year of fee payment: 14
2010-07-25	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
SK282155B6 (sk)	2001-11-06	Trisubstituované fenylové deriváty, spôsoby ich prípravy, ich použitie a farmaceutické prostriedky obsahujúce tieto deriváty
JP2006511445A (ja)	2006-04-06	マクロファージ遊走阻止因子（ｍｉｆ）のサイトカインまたは生物学的活性を阻害するナフタレン誘導体
JPH0570400A (ja)	1993-03-23	ベンジルオキシフエニル誘導体
EP0272478B1 (en)	1993-01-20	Glycyrrhetic acid derivatives and use thereof
JPH11506453A (ja)	1999-06-08	水溶性カンプトテシン類似体
JPH05213828A (ja)	1993-08-24	ビス（フェニル）エタン誘導体
EP0717027B1 (en)	1999-05-12	Diarylheptanoide derivative and pharmaceutical composition comprising the same
FUJIMOTO et al.	1986	Studies on the Metabolites of Penicillium diversum var. aureum. II.: Synthesis and Cytotoxic Activity of Trihydroxytetralones
EP1118324A1 (en)	2001-07-25	Analgesic agent comprising a cyclobutanedicarboxylic acid derivative
US6166074A (en)	2000-12-26	Pharmaceutical compositions
CN1056599C (zh)	2000-09-20	双(苯基)乙烷衍生物
CN116751244B (zh)	2025-07-15	α,β-不饱和羰基类18β-甘草次酸衍生物及其制备方法与应用
KR102307045B1 (ko)	2021-09-30	카페익산 에스테르 유도체를 유효성분으로 함유하는 아토피 피부염 예방 또는 치료용 조성물 및 이의 합성방법
JP2021512171A (ja)	2021-05-13	ペンタフルオロスルファニル置換アミド誘導体、そのための製造方法およびその医学的使用
EP1674101B1 (fr)	2007-11-14	Dérivés cinnamates de benzo [b]pyrano[3,2-h]acridin-7-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN119161302A (zh)	2024-12-20	蛇足石杉碱衍生物、其制备方法及其在抗痛风药物中的应用
JPS62205043A (ja)	1987-09-09	９，１０−ジヒドロ−フエナントレン誘導体およびその製法
JPH075460B2 (ja)	1995-01-25	制癌剤
PL170468B1 (pl)	1996-12-31	Sposób wytwarzanianowych pochodnych bis(fenylo)etanu
WO1992001706A1 (fr)	1992-02-06	Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention
JPH11255756A (ja)	1999-09-21	４−（置換アミノカルボニル）オキサゾール誘導体及び抗癌剤
JPH10147551A (ja)	1998-06-02	ヒドロナフタレン誘導体を有効成分とする抗炎症剤、抗癌剤及び新規ヒドロナフタレン誘導体
JPH01316397A (ja)	1989-12-21	１１β，１７α，２１―トリヒドロキシ―１，４―プレグナジエン―３，２０―ジオン　２１―〔（Ｅ，Ｅ）―３，７，１１―トリメチル―２，６，１０―ドデカトリエノアート〕及びこれを含有する抗炎症剤
KR20040084441A (ko)	2004-10-06	새로운 항암성 비타민 ｄ₃유도체
WO2010032582A1 (ja)	2010-03-25	成人ｔ細胞白血病治療薬